In addition to chemotherapy, about two-thirds of patients under 40 generally present with a hormone receptor positive tumour and will therefore receive a ten-year treatment regimen with tamoxifen with or without a GnRH agonist. The gene discussed is NR4A1; the disease is neoplasm.